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Abstract
Background: Randomised controlled trials of healthcare interventions depend on the participation of volunteers
who might not derive any personal health benefit from their participation. The idea that altruistic-type motives are
important for trial participation is understandably widespread, but recent studies suggest considerations of
personal benefit can influence participation decisions in various ways.
Methods: Non-participant observation of recruitment consultations (n = 25) and in-depth interviews with people
invited to participate in the UK REFLUX trial (n = 13).
Results: Willingness to help others and to contribute towards furthering medical knowledge featured strongly
among the reasons people gave for being interested in participating in the trial. But decisions to attend
recruitment appointments and take part were not based solely on consideration of others. Rather, they were
presented as conditional on individuals additionally perceiving some benefit (and no significant disadvantage) for
themselves. Potential for personal benefit or disadvantage could be seen in both the interventions being evaluated
and trial processes.
Conclusions: The term ‘conditional altruism’ concisely describes the willingness to help others that may initially
incline people to participate in a trial, but that is unlikely to lead to trial participation in practice unless people also
recognise that participation will benefit them personally. Recognition of conditional altruism has implications for
planning trial recruitment communications to promote informed and voluntary trial participation.
Trial registration: ISRCTN15517081
Background
Randomised controlled trials of healthcare interventions
depend on the participation of volunteers who might
not be expected to derive any personal health benefit
from the interventions being evaluated (beyond that
which they might reasonably expect to derive from
healthcare outside the trial). It is therefore widely
assumed that altruistic-type motives are important for
trial participation. But because trial participants might
not derive any personal health benefit from their partici-
pation, and because trial participation can bring with it
various burdens, it is widely recognised that potential
volunteers should be carefully informed about the trial
and enabled to consider the personal implications of
participation before deciding whether or not to
volunteer.
Many trials recruit fewer participants than anticipated
[1-3], although the feasibility of recruiting sufficient par-
ticipants to yield useful results is usually carefully esti-
mated. A study of recruitment in a cohort of 114 UK
multicentre trials funded by the UK Medical Research
Council and the UK Health Technology Assessment
Programme between 1994 and 2002 found that fewer
than a third (31%) achieved their original recruitment
target and half (53%) were awarded an extension. The
proportion achieving targets did not appear to improve
over time [4].
Concern to improve trial recruitment processes to
facilitate the participation of sufficient numbers of
appropriately informed volunteers has helped to * Correspondence: s.k.mccann@abdn.ac.uk
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any medium, provided the original work is properly cited.stimulate an interest in studies of patients’ perspectives
on trial recruitment processes and trial participation. A
number of rigorous qualitative investigations have gen-
erated important insights into factors that can influence
trial participation, the understandings (and misunder-
standings) that people have about (aspects of) trials that
they (are asked to) participate in, and the retrospective
reflections and evaluations of participation experiences
[3,5-28].
Alongside this primary research, we also conducted a
meta-ethnographic synthesis of qualitative studies of
potential volunteers’ accounts of issues influencing their
decisions about trial participation. The meta-ethno-
graphic synthesis is being written up for separate publi-
cation, but we note briefly here that 12 studies
published prior to 2006 met our inclusion criteria
[3,6,7,9,12,18,19,21-23,26,27]. These were considered
chronologically and the concepts identified as salient by
the original authors were extracted and compared. We
grouped the concepts into four key concept groups
relating to: a) personal circumstances at the time of trial
entry; b) views about the interventions being compared
in the trial; c) views about trial processes and proce-
dures; and d) the ‘weighing up’ of possible benefits to
self and to others of participating in the trial.
We contribute to and extend this literature with our
report of a study that aimed primarily to explore
patients’ perspectives on recruitment to and participa-
tion in a multi-centre trial (the REFLUX trial) that com-
pared medical and surgical interventions for patients
with gastro-oesophageal reflux disease (GORD), and
that included parallel patient preference arms within its
design. We paid particular attention to people’s
accounts of their decisions about whether or not to
participate.
The REFLUX trial
The REFLUX trial was set up to assess the effectiveness
and cost effectiveness of minimal access surgery com-
pared with continued optimised long term medical man-
agement amongst people with GORD [29]. GORD is a
chronic condition that causes some of the most fre-
quently seen symptoms in both primary and secondary
care; between 20% and 30% of ‘Western’ patients experi-
ence heartburn and/or reflux intermittently [30-32].
Reflux is the backflow of acid from the stomach into the
oesophagus and occurs when the valve at the lower end
of the oesophagus does not function properly. The usual
symptom is heartburn, and for some people, reflux can
become frequent and severe enough to require daily
medication for symptom control.
The treatment of GORD includes both medical and
surgical options. Medical management involves stepped
therapy resulting in the daily use of proton pump
inhibitors (PPIs) [33]. Once started on PPIs, the majority
of patients with significant GORD remain on long-term
treatment [34,35]. Whilst PPIs are generally assumed to
be safe, there are concerns regarding their long-term
use [36].
The role of surgery in treatment of GORD is conten-
tious and ill defined [37]. Currently patients only have
access to anti-reflux surgery if their long-term medica-
tion is failing to control their symptoms. Although sur-
gery seems highly effective for controlling GORD in the
short-term, it is unclear whether the benefits of surgery
remain long term.
The REFLUX trial focused on people with GORD
whose symptoms would otherwise be managed with
long term therapy with PPIs. Patients were eligible for
the REFLUX trial if they already required maintenance
medical therapy, had documented evidence of GORD,
symptoms for more than 12 months, were suitable for
either medication or surgery; and the recruiting clinician
was uncertain as to which management policy was bet-
ter for the patient.
A l t h o u g ht h eR E F L U Xt r i a lw a sp r i m a r i l yaR C T ,i t
also included parallel non-randomised patient prefer-
ence groups in recognition that the marked differences
in the treatments were likely to make the choice
between them strongly preference sensitive. Patients
who refused randomisation because of strong prefer-
ences (for medication or surgery) were allowed to access
their treatment of choice and be followed up within the
study [38,39]. Within the partially-randomised patient
preference trial design, potential participants who did
not express strong treatment preferences were rando-
mised in the conventional way. However, for logistical
reasons and to maintain a balance between the sizes of
the preference and randomised groups, the number of
participants that could be recruited to the preference
arms was restricted to 20 participants per intervention
in each recruitment centre. When this quota was
reached, patients could only participate in the rando-
mised arm of the trial. The trial, which was conducted
in 21 centres across the UK, recruited a total of 357
randomised participants (178 surgical, 179 medical) and
453 preference participants (261 surgical, 192 medical).
Participants in the medication arm of the trial contin-
ued on their PPIs with no further tests or follow up
appointments required. In contrast, participants in the
surgical arm of the trial had to undergo additional
investigative procedures (pH manometry test, and an
endoscopy procedure if they had not had one pre-
viously), and attend an outpatient appointment with the
surgeon prior to the anti-reflux surgery. Following sur-
gery, participants required between two and six weeks
off work for recovery. All participants were asked to
complete baseline and follow up questionnaires.
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Methods
This qualitative study was embedded in the REFLUX
trial. It aimed to examine in-depth people’s experiences
of trial recruitment and participation. A combination of
methods was used: non-participant observations of
recruitment appointments, followed by in-depth inter-
views with the people who were deemed eligible and
invited to participate in the REFLUX trial.
Between April 2003 and May 2004, SM approached a
total of 26 people in two trial recruitment centres (Cen-
tres A and B to preserve anonymity) to join this qualita-
tive study. Only one person declined to participate. SM
observed the recruitment appointments of the 25 people
who consented (13 in Centre A and 12 in Centre B).
She made field notes of key observation points during
and after the appointments, but did not audio- or video-
record the consultations. The observations were used to
give the research team insight into what was happening
in practice in recruitment appointments, to help identify
issues to explore with potential trial participants in
interviews, and to provide contextual information to
support interpretation of the interview data.
Eleven of the people whose consultations were
observed (5 in Centre A and 6 in Centre B) were judged
by the recruiting clinicians to be ineligible for the
REFLUX trial. They were subsequently excluded from
this qualitative study.
Of the 14 people deemed eligible for REFLUX partici-
pation, one subsequently declined to be interviewed. For
the remaining 13 people SM arranged face-to-face inter-
views (regardless of whether or not they agreed to parti-
cipate in the REFLUX trial).
Interviews were conducted by SM, either in partici-
pants’ homes, at the recruitment hospital or the study
research office. All but two took place approximately
one week after recruitment appointments (two partici-
pants asked to be interviewed immediately after their
recruitment appointments). The interviews aimed to
explore people’s experiences of the recruitment process
and to identify the factors that they thought had influ-
enced their decisions to attend the recruitment appoint-
ment and then to accept or decline trial entry. The
interviews were conversational in style, but SM used a
topic guide to help ensure that each person was invited
to describe the story of their GORD and its treatment
to date, to describe and reflect on each stage of the
recruitment process (letter of invitation or advert; sche-
duling of recruitment appointment; recruitment visit;
communication with members of the trial team after the
recruitment appointment); to express their opinions
about trial recruitment communications; and to discuss
what they had thought about and what had been influ-
ential in their decisions to participate or not in the trial.
At the time of these interviews, participants had con-
sented or declined to take part in the REFLUX trial, but
those who had agreed to randomisation did not know
the treatment to which they had been allocated.
The research ethics committee required that intervie-
wees be sent a copy of their transcript to read and
offered an opportunity to suggest any amendments they
wished to make. None of the interviews suggested any
amendments to their transcripts. Data analysis started
from the first observation and was an ongoing process
that informed data collection in the later stages of the
study (mainly by suggesting issues to probe in more
detail in later interviews) [40]. Data were analysed the-
matically with the assistance of a computerised qualita-
tive data analysis package (QSR Nvivo 2.0) [41].
The first stage involved familiarisation with the data.
Initial (open) codes were generated, discussed among
the team and grouped according to the stages of recruit-
ment processes that they referred to and/or into the-
matic categories relating to the types of experiences,
considerations or reasons that seemed salient from par-
ticipants’ perspectives. The second stage of analysis
involved developing and refining thematic categories,
and examining the relationships within and between
them, bearing in mind the chronological sequences
within individual accounts. SM led the analysis and
undertook the systematic coding of transcripts. MC and
VE contributed to the generation and refinement of
open codes and thematic categories, and to the consid-
eration of relationships that resulted in the findings pre-
sented here. In the illustrative data extracts below,
names of centres, doctors and participants have been
replaced by numbers and letters to preserve anonymity.
As part of the consent process, participants were
informed that the results of the study would be pub-
lished in academic journals.
Results
Five women and eight men were interviewed for this
study. Five of them had been taking prescribed acid-sup-
pression medication for GORD for at least five years.
Some still had poor symptom control, and some had
concerns about taking long-term medication. Most were
prescribed their acid-suppression medication by a gen-
eral practitioner, and several had not consulted a specia-
list about their GORD (prior to the REFLUX trial
recruitment appointment).
Nine of the thirteen people interviewed had agreed to
be randomised; two had agreed to join the preference
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declined to take part in the trial (both in centre A).
(The preference arm was not available in centre A at
the time of this study as its quota for preference partici-
pants was reached before SM started observing clinics).
Table 1 summarises the characteristics of the 13 study
participants.
When discussing their decisions about whether or not
to attend a REFLUX trial recruitment appointment and
whether or not to participate in the trial, people men-
tioned a number of considerations and portrayed these
as having been more or less influential. Our main find-
ings were (i) that willingness to help others and to con-
tribute towards furthering medical knowledge featured
strongly among the reasons people gave for being inter-
ested in participating in the trial, but (ii) decisions to
take part were also presented as conditional on indivi-
duals additionally perceiving some benefit (and/or no
significant disadvantage) for themselves. In this section,
we focus first on the initial willingness to help others
and then describe the ways in which people considered
they might either benefit or not benefit personally from
attendance at a REFLUX trial recruitment appointment
and from participation in this trial.
A schematic overview of the ways in which these main
categories of consideration were described as having
influenced participation in the REFLUX trial is pre-
sented in Figure 1.
a) Initial inclination to participate to help others
In interviews, people explained that they had been moti-
vated to attend the trial recruitment appointment and
possibly take in the trial at least in part because they
had an inclination to help others or help generally:
“The reason I wanted to try it is because, they’re
obviously trying to find the recommended solution to
heartburn or which is the best way for doing it.....if I
c a nh e l pi na n yw a yt os o r to ff i n dw h e r et h eb e s t
way forward it, then I was quite keen to just help out
and do that.” (Centre B/Dr C/Pt 6/randomised
surgical)
“It sounds corny, but I just want to be of some assis-
tance....I could have taken the easy option, which is
always the easy option, just to say ‘No, I’m not inter-
ested’. But nobody benefits from that.” (Centre A/Dr
B/Pt 14/randomised surgical).
However, this initial willingness was not necessarily
their only motivator to attend a trial recruitment
appointment, and it was not presented as a sufficient
reason for taking part in the trial. In the next two sec-
tions, we consider perceptions of potential for personal
b e n e f i tt h a tt e n d e dt oe n c o u rage participation and per-
ceptions of potential for personal disadvantage that
tended to discourage it.
b) Potential to benefit personally
People identified a number of ways in which they might
benefit personally from attending the initial recruitment
appointment and (possibly) from taking part in the trial.
These were strongly related to their understandings of
their current situation and of the health care options
available to them outside the trial.
Table 1 Summary characteristics of qualitative study participants
Participant
number
Gender and approximate age of
participants




1 Female early 40 s 8 years A Randomised
2 Female early 50 s 5 years A Declined
3 Female mid 40 s 10-13 years A Randomised
4 Male mid 60 s 6 years A Randomised
5 Male early 20 s 2-3 years B Preference medical
6 Male early 30 s 4-5 years B Randomised
7 Male early 50 s 18 months B Preference medical
8 Female early 60 s 18 months -2 years A Declined
9* Female early 20 s 12 -18 months B Randomised
10 Male late 30 s 1 year A Randomised
11 Female mid 50 s 8 years A Randomised
12 Male early 50 s 1 year B Randomised
13 Male mid 40 s 1 year B Randomised
14 Male late 40 s 18 months - 2 years A Randomised
*Participant 9 initially consented to joining the qualitative study and to participate in the REFLUX trial. However, she did not respond to any subsequent
communications and so contributed no data to the study.
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learning and review
Several people mentioned that the trial recruitment
appointment had presented an opportunity to have their
condition and treatment reviewed by a specialist, and/or
for them to learn more in the context of a personal con-
sultation than they could by general reading about
GORD. For example:
“I just thought it would be a good chance to discuss
things, em, find out more for myself, and then also
help other people in the future with the same sort of
thing....it was as much selfish reasons as wanting to
help other people! Cos I wanted to find out more
information, em I find you get better information,
you know, face-to-face conversation than looking at
random studies on the internet...” (Centre B/Dr C/pt
5/preference medical)
Our observations revealed that information provision
by clinicians and question-asking by patients were both
quite variable across recruitment appointments. Some
clinicians gave the impression of being very rushed,
while others worked through discussions and examina-
tions at a steadier pace and seemed to be more thor-
ough. Not all patients asked questions when offered the
opportunity to do so.
￿ Trial participation potentially offering access (and faster
access) to surgery
Most of the people who had agreed to be randomised
within the REFLUX trial indicated at some point in
their interviews for this study that they were hoping to
be allocated to surgical treatment because this repre-
sented an opportunity to possibly improve their symp-
toms (if these were not alleviated by medication alone)
and/or to stop taking long term medications. For exam-
ple:
“You know, I’ve already had tablets for 8 years, so, I
just hope, well I hope, that that comes into it.....I am
hoping that I’ll be randomised to get an operation.”
(Centre A/Dr A/Pt 1/randomised medical)
“I’ll be perfectly honest, I would probably choose to go
on the surgery, em, because I’ve been on tablets for a
while, and, intermittently been off the tablets and the
symptoms keep coming back, it would be interesting
possibly to try alternative method to see if that’s
going to be a success for me personally.” (Centre B/
Dr C/Pt 6/randomised medical)
None of the people who expressed a preference for
surgery in the interviews for this study had been
observed to disclose a preference for surgery in their
recruitment appointments, and observation notes record
that some had explicitly said that they had no prefer-
ence between the treatments or were undecided which
would be best for them.
Several of the people who were inclined to favour sur-
gery had also thought they might access surgery more
quickly in the context of the REFLUX trial. They saw
this as a reason in favour of participation. For example:
“One of my reasons for, I would like to take part in
it, I would think, I might maybe get some quicker
treatment? Because I had gallbladder trouble nine
years ago and I waited a long time for any treat-
ment, and I was in a lot of pain, so, maybe...I
thought that I would get quicker treatment.” (Centre
A/Dr A/Pt 1/randomised medical)
We did not observe any evidence of clinicians suggest-
ing in recruitment appointments that people allocated to
the surgical arm of the trial would be treated more
quickly than people receiving surgery outwith the trial.
￿ Trial participation offering careful monitoring
A couple of interviewees said they thought their condi-
tion would be more closely ‘monitored’ if they partici-
pated in the REFLUX trial, and that this had increased
their inclination to participate. For example:
“Well again, it’s going to be monitored over the years
isn’t it?....in this study they are gonna keep their eye
on you...I mean you go along to change your medica-
tion but somehow there may well be more thought
put behind it, you know, the monitoring. Whereas
your doctor doesn’t have time, you know? “ (Centre
A/Dr A/Pt 11/randomised medical)
The expectation of closer monitoring in the context of
the trial might have derived from a prior general under-
standing of what trials entail, or perhaps from the parti-
cipant information leaflet, which explained that a
number of questionnaires would be sent to trial partici-
pants. We did not observe any discussion of the poten-
tial benefits (or disadvantages) of trial participation in
terms of follow-up assessments for individual patients in
the trial recruitment appointments.
c) Personal concerns or lack of potential for personal
benefit from trial participation
The two study participants who declined to take part in
the REFLUX trial both described how initially they had
wanted to help others and had considered participating
for this reason. However, their accounts suggest their
initial willingness to participate had lessened as they
l e a r n e dm o r ea b o u tt h et r i a ld u r i n gt h er e c r u i t m e n t
appointment and developed concerns about negative
implications for themselves - especially if they were
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good symptom control with medication. One was appre-
hensive about undergoing an unpleasant pre-surgical
test (pH test) and the other thought the risks of under-
going surgery were unwarranted given her current con-
dition:
“No the keyhole surgery, no that doesn’tb o t h e rm e ,
it’s just the thought of that test.” (Centre A/Dr A/Pt
8/declined trial entry)
“I would have liked to have helped with the research
and what have you, but em, I just didn’tf e e lIw a s
ready for it [surgery] at this moment in time...I know
it’s keyhole surgery, but things can go wrong with key-
hole surgery...and I feel that unless I’mi na na w f u l
lot of pain I’m quite willing to take the medication to
keep it under control, rather than having the opera-
tion. In the future if I’m still having problems, and I
probably think it’s the right thing to do I would prob-
ably opt for the surgery, but only much further down
the line if that was really the only option left...but
I’m reluctant right now..What if it doesn’t work out,
would things end up worse off than they are just
now?.” (Centre A/Dr A/Pt 2/declined trial entry)
For these people, an initial inclination to participate in
the trial did not lead on to trial participation because of
concerns that participation would involve exposing
themselves to unnecessary potential harms. The two
people in centre B who declined to be randomised but
agreed to take part in the preference medical arm of the
REFLUX study expressed similar concerns about the
pre-surgical tests and surgery.
Discussion
The main findings of this study were that people
reported having an inclination to help others or contri-
bute to a collective general good that predisposed them
towards trial participation, but that considerations of the
implications of trial participation for them personally
also featured in their accounts as influential reasons for
or against participation. For the people who agreed to
be randomised, trial participation seemed to be some-
thing of a “win:win” situation - one in which they could
both help others and benefit (or at least not be harmed)
personally. Both trial processes (such as attending
recruitment appointments that included specialist
assessments, and undergoing additional symptom moni-
toring as part of trial follow up) and trial interventions
(such as pre-surgical tests and surgery) were considered
by potential participants as sources of benefit or harm.
Some participants, however, had misconceptions about
these.
Our study had several strengths. We conducted obser-
vations as well as interviews, and the interviews about
trial recruitment experiences were conducted within a
week of trial recruitment appointments. Our study is
one of the first to examine potential participants’ per-
spectives on trial recruitment in the context of trial that
had patient preference arms. However, we only recruited
participants from two trial recruitment sites, and only
one of these was still offering participation in preference
a r m sb yt h et i m ew ew e r ea b l et oc o n d u c ti n t e r v i e w s .
Our sample size, and the number of participants who
declined randomisation but accepted follow up in a pre-
ference arm, were therefore limited.
This study is not the first to show that people cite a
desire or willingness to help others among the factors
motivating their participation in clinical trials,
[1,3,12,13,16,27] nor, indeed to show that perceptions of
potential for individual benefit also feature in their con-
siderations [7,9,10,12-15,17,28]. However, our findings
help illuminate the relationship between consideration
for others and considerations for self in the context of
trial participation.
When consideration of others motivates action, it is
sometimes referred to as ‘altruism’. ‘Altruism’ is a con-
tested concept, not least because of the multiple chal-
lenges of differentiating considerations of others from
considerations of self. Opinions vary as to whether the
term should only be used when consideration of others
is the sole or overriding motivator, and/or whether it
should only be used when personal interests are some-
how harmed at the same time as others’ or collective
interests are promoted.
These and other theoretical and practical issues have
led to the development of a number of variants to the
basic concept of altruism [42,43]. In the context of clini-
cal trials, the term ‘weak altruism’ [44] has been pro-
posed to describe a situation where patients consent to
participate only because they perceive ‘no positive net
difference’ between treatments and so do not expect to
lose out. Canvin and Jacoby [13] drawing on their study
of people being invited to take part in an epilepsy trial,
suggest that this term can be usefully extended to
describe the situation where people are “happy to help
others, but only where they could also help themselves.”
We suggest that the term ‘conditional altruism’ might
more accurately describe what was observed in our
study. It summarises the finding that although people
may initially have a tendency to participate in a trial
based on a willingness to help others or contribute to a
general good, this is unlikely to lead to trial participation
in practice unless people can also recognise that trial
p a r t i c i p a t i o nc a nb e n e f i t( o ra tl e a s tn o th a r m )t h e m -
selves in ways that they regard as salient.
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that suggests people’s decisions about whether or not to
take part in trials are sometimes influenced by miscon-
ceptions about how, why and to what extent they might
benefit personally from participation [5,7,9,18,23,26] -
even when they have been given information materials
that conform to current trial regulations and have spo-
ken with clinically qualified trial staff. They suggest
there is no room for complacency in trial recruitment
communication. They also tend to confirm that people
for whom a current standard treatment is not working
well are likely to regard trial participation as a positive
opportunity to access a new intervention that could be
better [21], and that people who agree to be randomised
may harbour preferences for particular treatments that
trialists are unaware of [5]
Implications for trialists
The notion of ‘conditional altruism’ draws attention to
the idea that while altruistic tendencies can encourage
trial participation, such participation is still conditional
on perceptions of personal benefit and an absence of
overriding concerns. This raises some important ques-
tions about how trialists should communicate with
(potential) participants - especially given the evidence
that (potential) participants may hold or develop mis-
conceptions about the ways in which they might benefit
from or be disadvantaged by trial participation.
Assuming that the goals of recruitment communica-
tions are to invite and encourage people to participate
in trials for which they are eligible, but also to ensure
that their decisions about participation are based on
an understanding of what is at stake and are congruent
with their own values and good reason, our findings
suggest that trialists need to strive to enable people to
understand and consider the various ways in which
both others and themselves might benefit, as well as
the various ways in which their own interests might be
poorly served by trial participation. Trial recruitment
communication might usefully enable people to con-
sider whether they are in a “win: win” situation in
which both they and others might benefit from their
participation.
The promotion of consideration for others as a reason
for participating in research does raise ethical issues but
will not necessarily be inappropriate [45]. Others’ inter-
ests may be seen as bound up with self interest in var-
ious ways - not least when satisfaction or social credit
are derived from promoting the interests of needy or
deserving others. The promotion of consideration of
potential for personal benefit from trial participation is
also ethically sensitive, particularly in the light of aware-
ness that people sometimes have unrealistic ideas about
what they might gain and how from trial participation.
Clearly, trialists should not over-state the case for any
potential for personal benefit that might be derived
from trial participation. Our study suggests that more
positive steps need to be taken to ensure both collective
and personal issues are considered, and to avoid and
address any potential misconceptions about the implica-
tions of trial participation. This includes misconceptions
that people ‘bring into’ trials or ‘develop’ from what they
are told - some of the misconceptions observed in this
study could not be simply and directly attributed to trial
recruitment materials or consultations.
A number of strategies might be adopted. The types of
misconception that have been identified in several stu-
dies might now be anticipated, and pre-trial discussions
or research with members of the groups of people who
will be eligible for trial participation could also help
identify any new or specific misunderstandings that
might arise in the context of particular trials, and the
ways in which potential participants’ hopes or fears
might tend to be unduly heightened. Once identified,
these issues can be addressed explicitly in information
materials [46].
Trial recruitment decision aids might also be useful as
a means of enabling and encouraging potential partici-
pants to engage with information and consider the key
implications of their trial participation options. A deci-
sion aid that was developed to improve the consent pro-
cess for women invited to participate in a breast cancer
prevention trial was recently reported to have been
helpful to the women as they considered trial participa-
tion, and it resulted in a greater understanding com-
pared to reading a participant information sheet [47].
However, trialists who develop recruitment decision aids
will need to work through a range of issues. Decisions
about how to structure the trial participation options
(especially when there are preference arms to be consid-
ered), how to present trial interventions and procedures,
and which potential collective and personal issues to
mention and associate with which option features will
all need to be carefully considered [48].
The potential importance of two-way interpersonal
communication for the support of informed trial partici-
pation decisions that take both social and personal con-
siderations into account should not be underestimated.
The variability of recruitment consultations observed
and participant understandings expressed in our rela-
tively small study support the need to identify and culti-
vate more effective approaches to communication
among trial recruitment staff as well as to attend to
more standardised information resources. Decision aids
that encourage people to indicate preferences and dis-
cuss these with their clinicians or trial recruitment per-
sonnel might also help expose uncertainties or
misunderstandings that could then be addressed before
McCann et al. Trials 2010, 11:31
http://www.trialsjournal.com/content/11/1/31
Page 8 of 10decisions about participation were finalised. But with or
without these, careful discussions of what individuals
hope to contribute to others and gain or avoid for them-
selves could be crucial to help avoid situations in which
people’s decisions to participate are based at least in
part on misunderstandings about their potential to ben-
efit [49].
Conclusions
Willingness to make a contribution to the collective
good and to help others is commonly thought to be -
and relied upon as - a key motivating factor for partici-
pation in clinical trials. However, the relationship
between a willingness to help others and other factors
that might bear on trial participation is complex. The
term ‘conditional altruism’ concisely captures the
insights from this study that although willingness to
help others might generally incline people towards parti-
cipation, participation is still conditional on expectations
of benefiting personally to some extent. A more
informed understanding of motivations to participate in
a trial, and of the kinds of beliefs that underpin these,
could usefully underpin the knowledge and practice of
trial recruiters as they attempt to grapple with the com-
plexities of trial recruitment and make judgements
about how best to support people making decisions
about trial participation.
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